[Amended] Material event report (decision to redeem own convertible bonds early)

What happened

Material Event Report (Decision to Acquire Own Convertible Bonds Before Maturity) HLB Therapeutics Inc.

Amendment Report August 20, 2026

1. Disclosure document subject to amendment: Material event report (decision to acquire own convertible bonds before maturity) 2. Original filing date of the disclosure document subject to amendment: August 7, 2026 3. Amendments Item 8. Acquisition amount: Reason for amendment - change by agreement with the bondholder; Before - 5,074,736,000; After - 5,076,771,373 Item 8. Scheduled payment date of acquisition amount: Reason for amendment - change by agreement with the bondholder; Before - August 20, 2026; After - August 31, 2026

Material Event Report / Matter Subject to Exchange Reporting Obligation To: Financial Services Commission / Korea Exchange Date: August 20, 2026 Company name: HLB Therapeutics Inc. Representative Director: Gi-hong An Head office address: 2nd floor, 202, 6 Sanmaru-ro, Guri-si, Gyeonggi-do (Galmae-dong) Phone: 031-786-7800 Website: https://hlbtherapeutics.com Preparer: Title: Managing Director, Name: Yeong-in Han, Phone: 031-786-7800

Decision to Acquire Own Convertible Bonds Before Maturity 1. Type of bonds: Series 18; Type: Unregistered, unsecured, privately placed convertible bonds 2. Bond issue date: February 28, 2025 3. Bond issuance method: Private placement 4. Bond maturity date: February 28, 2028 5. Total face (electronically registered) value of the bonds (KRW): 5,000,000,000 6. Face (electronically registered) value of bonds subject to acquisition (KRW): 5,000,000,000 7. Acquisition decision date: August 6, 2026 8. Acquisition amount: Amount (KRW) 5,076,771,373; Basis of calculation - principal and interest; Payment (scheduled) date August 31, 2026; Source of acquisition funds - offset against paid-in funds from a third-party-placement rights offering 9. Acquisition method: Over-the-counter purchase 10. Reason for acquisition before maturity: Bondholder's exercise of early redemption right (put option) 11. Future handling plan: Cancellation of the registered bond with the Korea Securities Depository 12. Matters concerning conversion: Conversion ratio (%) 100; Conversion price as of the report date (KRW/share) 6,782; Type of shares to be issued upon conversion - HLB Therapeutics Inc. registered common shares; Number of shares 737,245; Ratio to total shares outstanding (%) 0.83; Conversion request period Start date February 28, 2026, End date January 27, 2028 13. Remaining face (electronically registered) value of the bonds after acquisition (KRW): 0 14. Whether subject to filing with the Fair Trade Commission: Not applicable 15. Other matters for reference in investment decisions 1) The "7. Acquisition decision date" above is the board resolution date. 2) The "Amount" under "8. Acquisition amount" above is the sum of principal and interest, and the "Payment (scheduled) date" is the early redemption date. 3) The "Conversion price as of the report date" under "12. Matters concerning conversion" above reflects adjustments for market price changes and bonus issues since issuance. 4) The "Shares to be issued upon conversion" under "12. Matters concerning conversion" above is the number of shares to be issued and the ratio to total shares outstanding, calculated on the assumption that the entire face value of the convertible bonds to be acquired this time is converted.

[Matters concerning the seller] Seller name: HLB Co., Ltd.; Relationship with the company or largest shareholder: Largest shareholder; Background of selection: Selected by the board of directors to achieve management objectives; Transactions and plans within 6 months before and after the acquisition decision: -; Face value of bonds sold (KRW): 5,000,000,000; Remarks: -

[Where the seller includes the company's largest shareholder or a related party thereof] Seller name: HLB Co., Ltd.; Relationship with largest shareholder: Itself; Shares held at the time of convertible bond issuance - Number of shares 6,696,809, Ratio (%) 7.96; Shares to be issued upon conversion - Number of shares -, Ratio (%) -; Remarks: -